Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.
Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA; International High Risk Melanoma Consortium. Broman KK, et al. Among authors: fleming md. Ann Surg. 2023 May 1;277(5):e1106-e1115. doi: 10.1097/SLA.0000000000005370. Epub 2023 Apr 6. Ann Surg. 2023. PMID: 35129464 Free PMC article.
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P. Zager JS, et al. Among authors: fleming md. BMC Cancer. 2018 Feb 5;18(1):130. doi: 10.1186/s12885-018-4016-3. BMC Cancer. 2018. PMID: 29402264 Free PMC article.
Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
Vetto JT, Hsueh EC, Gastman BR, Dillon LD, Monzon FA, Cook RW, Keller J, Huang X, Fleming A, Hewgley P, Gerami P, Leachman S, Wayne JD, Berger AC, Fleming MD. Vetto JT, et al. Among authors: fleming a, fleming md. Future Oncol. 2019 Apr;15(11):1207-1217. doi: 10.2217/fon-2018-0912. Epub 2019 Jan 29. Future Oncol. 2019. PMID: 30691297 Free article.
Traveling for Pancreatic Cancer Care Is Worth the Trip.
Alvarez MA, Anderson K, Deneve JL, Dickson PV, Yakoub D, Fleming MD, Chinthala LK, Zareie P, Davis RL, Shibata D, Glazer ES. Alvarez MA, et al. Among authors: fleming md. Am Surg. 2021 Apr;87(4):549-556. doi: 10.1177/0003134820951484. Epub 2020 Oct 28. Am Surg. 2021. PMID: 33108886
Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis.
Broman KK, Hughes TM, Dossett LA, Sun J, Carr MJ, Kirichenko DA, Sharma A, Bartlett EK, Nijhuis AA, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma J, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras RM, Teras J, Farrow NE, Beasley GM, Hui JY, Been L, Kruijff S, Boulware D, Sarnaik AA, Sondak VK, Zager JS; International High-Risk Melanoma Consortium. Broman KK, et al. Among authors: fleming md. J Am Coll Surg. 2021 Apr;232(4):424-431. doi: 10.1016/j.jamcollsurg.2020.11.014. Epub 2020 Dec 13. J Am Coll Surg. 2021. PMID: 33316427 Free PMC article.
Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2).
Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Broman KK, et al. Among authors: fleming md. Cancer. 2021 Jul 1;127(13):2251-2261. doi: 10.1002/cncr.33483. Epub 2021 Apr 7. Cancer. 2021. PMID: 33826754 Free PMC article.
259 results